	US 11,701,411 B2
	Compositions and methods for treating gluten intolerance and disorders arising therefrom
David C. Schriemer, Chestermere (CA); and Martial Rey, Paris (FR)
Assigned to Codexis, Inc., Redwood City, CA (US)
Filed by Codexis, Inc., Redwood City, CA (US)
Filed on Nov. 23, 2020, as Appl. No. 17/102,290.
Application 17/102,290 is a continuation of application No. 15/382,560, filed on Dec. 16, 2016, granted, now 10,857,214.
Claims priority of provisional application 62/268,445, filed on Dec. 16, 2015.
Prior Publication US 2021/0093699 A1, Apr. 1, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/48 (2006.01); C12N 9/50 (2006.01); A61P 1/14 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01)

CPC A61K 38/488 (2013.01) [A61K 9/0053 (2013.01); A61K 38/48 (2013.01); A61K 45/06 (2013.01); A61P 1/14 (2018.01); C12N 9/63 (2013.01); C12Y 304/23012 (2013.01)]

31 Claims

1. A method for attenuating one or more symptoms of gluten intolerance in a patient in need thereof, which method comprises administering to the patient an effective amount of a pharmaceutical composition comprising neprosin, wherein the effective amount comprises a total daily protein ingested by the patient to enzyme ratio of between about 100:1 and about 15000:1, so as to cleave gluten into non-antigenic peptides, thereby attenuating said symptoms.